Home » Stocks » RETA

Reata Pharmaceuticals, Inc. (RETA)

Stock Price: $129.50 USD 1.12 (0.87%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $130.00 +0.50 (0.39%) Jul 23, 6:35 PM
Market Cap 4.70B
Revenue (ttm) 8.61M
Net Income (ttm) -266.27M
Shares Out 36.20M
EPS (ttm) -7.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $129.50
Previous Close $128.38
Change ($) 1.12
Change (%) 0.87%
Day's Open 128.96
Day's Range 126.41 - 130.97
Day's Volume 191,082
52-Week Range 76.34 - 186.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Reata Pharmaceuticals, Inc. (RETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...

3 weeks ago - Zacks Investment Research

PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management ...

1 month ago - GlobeNewsWire

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

2 months ago - Zacks Investment Research

The company might soon be taking a very big step toward FDA approval of an important pipeline drug.

2 months ago - The Motley Fool

The U.S. Food and Drug Administration (FDA) sent a communication to Reata Pharmaceuticals Inc. (NASDAQ: RETA) on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharmace...

2 months ago - Invezz

PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received ...

2 months ago - GlobeNewsWire

The major indices have all jumped as jobless claims fell to a fresh pandemic low. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to give you...

Other stocks mentioned: CEVA, AAL, BLNK, KEX
2 months ago - Forbes

Going into today, the Dow Jones continued its sell-off and fell more than 150 points while the S&P 500 lost 0.6% and the Nasdaq dipped more than 1%. Our AI has identified the following stocks rated To...

Other stocks mentioned: CVNA, RDFN, AMRS, BLNK
2 months ago - Forbes

Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

2 months ago - Zacks Investment Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 14.68% and -32.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st...

2 months ago - Zacks Investment Research

ANNOUNCES FDA ACCEPTED FOR FILING REATA'S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME

2 months ago - GlobeNewsWire

Reata Pharmaceuticals (NASDAQ:RETA) releases its next round of earnings this Thursday, May 06. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

2 months ago - Benzinga

PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management w...

2 months ago - GlobeNewsWire

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report fi...

2 months ago - GlobeNewsWire

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further ...

2 months ago - Zacks Investment Research

Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies

2 months ago - GlobeNewsWire

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ALXN, ATVI, BKR, BMRN, ESPR, FATE, FLXN
2 months ago - 24/7 Wall Street

PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment...

3 months ago - GlobeNewsWire

PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts ...

3 months ago - GlobeNewsWire

Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.

Other stocks mentioned: BCPC, BIO
4 months ago - GuruFocus

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome.

4 months ago - Zacks Investment Research

Reata Pharmaceuticals Inc (NASDAQ: RETA) has submitted a marketing application to the FDA for bardoxolone methyl (bardoxolone) to treat chronic kidney disease caused by Alport syndrome. Alport syndrome ...

4 months ago - Benzinga

Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 21.38% over the past year to ($1.25), which beat the es...

4 months ago - Benzinga

ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY'S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME

4 months ago - GlobeNewsWire

PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has sub...

4 months ago - GlobeNewsWire

PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will rep...

5 months ago - GlobeNewsWire

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Analysts are excited about these companies. Should you be, too?

Other stocks mentioned: SA, VHC
5 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between O...

7 months ago - Newsfile Corp

NEW YORK, Dec. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and...

7 months ago - PRNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United S...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October ...

7 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - December 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceu...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 10, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between ...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 10, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmace...

7 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc.

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 9, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class acti...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceut...

7 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

7 months ago - Business Wire

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RE...

7 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - December 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceut...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between O...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 7, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceu...

7 months ago - Newsfile Corp

PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its prev...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October ...

7 months ago - GlobeNewsWire

PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a pu...

7 months ago - GlobeNewsWire

PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of a propose...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that has been fi...

7 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - November 29, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between ...

7 months ago - Newsfile Corp

About RETA

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone t... [Read more...]

Industry
Biotechnology
IPO Date
May 26, 2016
CEO
J. Warren Huff
Employees
261
Stock Exchange
NASDAQ
Ticker Symbol
RETA
Full Company Profile

Financial Performance

In 2020, RETA's revenue was $9.02 million, a decrease of -65.99% compared to the previous year's $26.52 million. Losses were -$247.75 million, -14.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RETA stock is "Strong Buy." The 12-month stock price forecast is 237.00, which is an increase of 83.01% from the latest price.

Price Target
$237.00
(83.01% upside)
Analyst Consensus: Strong Buy